Market Context — Why This Technology, Why Now

The global demand for minimally invasive surgery continues to surge, driven by advancements in endoscopic techniques and a focus on patient outcomes and cost efficiency. Healthcare systems worldwide are seeking innovative solutions to enhance surgical precision, reduce recovery times, and optimize resource utilization. This technology directly addresses these pressures by improving the efficacy and safety of endoscopic procedures, positioning it as a critical enabler for the next generation of surgical interventions.

Key Competitive Advantages
01

Achieves sustained mucosal elevation for extended periods, significantly improving intraoperative visibility.

02

Ensures stable operability during endoscopic procedures by providing superior tissue adhesion, preventing material diffusion and leakage.

03

Establishes strong market leadership due to high novelty, with only three prior art documents cited by the examiner.

Market Opportunity
Endoscopic Surgery
$13.5B globally (AI est.)
The increasing adoption of minimally invasive surgery and technological innovations continue to expand the scope of endoscopic procedures, particularly in gastrointestinal surgery, driving demand for high-performance injection materials.
Global medical device manufacturers specializing in endoscopy Surgical instrument and supply companies Hospital systems focused on advanced surgical techniques
Gastroenterology
$350M domestically (AI est.)
As endoscopic treatment becomes standard for early detection and treatment of gastric and colorectal cancers, the importance of injection materials that support safer and more reliable procedures is increasing.
Pharmaceutical companies with GI portfolios Diagnostic and interventional endoscopy device companies Specialized GI clinics and research hospitals
Regenerative Medicine and Tissue Engineering
$6.5B globally (AI est.)
New applications are anticipated in tissue regeneration, such as long-term delivery of cells and drugs to the submucosal layer, and as scaffold materials for tissue engineering.
Biotech firms in regenerative medicine Companies developing drug delivery systems Biomaterials manufacturers for tissue scaffolds
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent features 14 broad claims, securing a robust scope that covers diverse compositions, manufacturing methods, and applications. The rapid grant of the patent, with only three prior art documents cited by the examiner, underscores the technology's high novelty and distinct advantage over existing solutions.

Competitive White Space

This patent primarily covers specific polymer-cyclodextrin compositions for endoscopic submucosal injection. White space exists in developing alternative material compositions for sustained tissue elevation or exploring drug delivery applications beyond direct submucosal injection.

Economic Impact
~$1.5M/year estimated cost and labor reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Implementing this technology could reduce average endoscopic surgery time by 10% and re-operation rates by 5%. For a medical institution performing 2,000 surgeries annually, the estimated cost savings are calculated as: (2,000 annual surgeries × 10 min average surgery time reduction × ~$6.50/hour for medical staff (AI est.)) + (5% re-operation rate reduction × ~$3,500 average re-operation cost (AI est.) × 2,000 surgeries). This totals an estimated ~$1.5M in annual cost savings (AI est.), directly reducing the burden on medical professionals.

Speed to Market
6× faster than in-house development
This technology benefits from completed fundamental research by a national R&D institute, with established material science mechanisms. This allows adopting companies to significantly reduce initial R&D, potentially starting directly from a product development phase. The specific composition of the polymer-cyclodextrin complex is defined, lowering development risks and potentially shortening time-to-market by approximately 2.5 years.
Competitive Positioning

X: Treatment Efficiency and Durability
Y: Safety and Minimally Invasive Nature

Business Models & Applications
🤝 Licensing to Medical Device Manufacturers
By licensing this technology to medical device manufacturers with existing endoscopic product portfolios, rapid market entry and monetization can be expected through their extensive sales channels and regulatory expertise.
🔬 Product Commercialization through Joint Development
Collaborating with pharmaceutical or medical device companies to develop specialized endoscopic injection materials could lead to high-value products tailored to specific needs, securing first-mover advantage.
🏭 In-house Manufacturing and Sales
Manufacturing and selling the injection material under an owned brand could secure high-profit margins, build brand value, and establish market presence. Developing a unique distribution network would be key.
Adjacent Application Opportunities
🦷 Dental and Oral Surgery
Periodontal Tissue Regeneration Material
Applicable as a regenerative promoter for gum and bone tissue in periodontal disease treatment. This technology's superior tissue adhesion and sustained elevation could function as a scaffold material in regenerative medicine, potentially enhancing treatment efficacy.
💅 Aesthetic Medicine
Long-Lasting Dermal Fillers
Potential for repurposing as aesthetic fillers for skin wrinkle improvement and volume enhancement. Its sustained elevation effect and high biocompatibility could differentiate it from existing products, leading to increased patient satisfaction.
🩹 Wound Healing and Skin Regeneration
Wound Dressings for Chronic Ulcers
Could be utilized as a wound dressing for treating chronic ulcers and bedsores, aiming to protect the affected area and provide a regenerative environment. Its high tissue adhesion is expected to maintain a stable wound healing environment.
Integration Roadmap — Estimated 36-Month Deployment
Phase 1: Technology Evaluation and Pre-clinical Planning
Duration: 6 months
Conduct detailed evaluation of the technology's foundational data, comparative verification with existing products, and initial regulatory requirement assessment. Concurrently, design and prepare protocols for pre-clinical studies using animal models.
Phase 2: Product Development and Pre-clinical Studies
Duration: 12 months
Initiate formulation studies for the injectable material, develop processes for mass production, and establish GMP-compliant manufacturing systems. Execute pre-clinical studies based on designed protocols to acquire fundamental safety and efficacy data.
Phase 3: Regulatory Submission and Market Launch Strategy
Duration: 18 months
Based on pre-clinical results, prepare submission documents for regulatory authorities in various countries/regions to obtain approval. Simultaneously, formulate post-market launch sales strategies, support systems for medical institutions, and continuous improvement plans.
Technical Feasibility
This technology relies on a specific material composition—a polymer-cyclodextrin complex—and could be integrated without significant changes to existing endoscopic injection devices or procedures. The patent claims clearly define the composition, suggesting relatively easy incorporation into existing medical device manufacturing lines and quality control processes. This reduces the need for large-scale capital investment or new infrastructure, facilitating smooth technology transfer and product commercialization.
Success Scenario
Adopting this technology could enable surgeons to focus on more precise procedures, as submucosal elevation in endoscopic surgery would be maintained stably for extended periods. This is expected to reduce average surgery times by 10% and lower complication risks. Patients could receive safer, higher-quality treatment, while medical institutions may improve operating room utilization, realizing economic benefits of several million USD annually and optimizing healthcare resource allocation.
Patent Record
APPLICATION NO.
特願2020-004869
REGISTRATION NO.
7387163
FILING DATE
2020/01/16
GRANT DATE
2023/11/17
EXPIRATION DATE
2040/01/16
PATENT HOLDER
国立研究開発法人物質・材料研究機構
Examination History
2022年11月30日
出願審査請求書
2023年11月07日
特許査定